Committed to sharing our science

Committed to sharing our science

405 results available

Aficamten, a Selective Small-Molecule Cardiac Myosin Inhibitor for the Potential Treatment of Hypertrophic Cardiomyopathy

Poster, Gordon Research Conference: Cardiac Regulatory Mechanisms, 2022
Sarkar SS, et al
New London, NH
June 26, 2022
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction The METEORIC-HF Randomized Clinical Trial

Journal of the American Medical Association
Lewis GD, et al
July 19, 2022
Early Cardiac Structural and Functional Reverse Remodeling in Obstructive Hypertrophic Cardiomyopathy after 10 Weeks of Aficamten Therapy: Analyses from REDWOOD-HCM

Poster, American Society of Echocardiography 2022
Abraham T, et al
Seattle, WA
June 11, 2022
Effects of Omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial

European Heart Journal
Metra M, et al
May 22, 2022
Efficacy and Safety of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Presentation, Heart Failure 2022
Masri A, et al
Madrid, Spain
May 23, 2022